Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 15/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | UTS2R | Q9UKP6 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15065006 | 0.81 | CNR2 (1.00) | CNR2ALDH1A1TSHR | |
| SCHEMBL15064471 | 0.80 | CNR2 (1.00) | CNR2ALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL15064416 | 0.78 | CNR2 (1.00) | CNR2ALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL15064654 | 0.78 | CNR2 (1.00) | CNR2ALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL15064495 | 0.78 | CNR2 (1.00) | CNR2ALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL15064748 | 0.73 | CNR2 (1.00) | CNR2ALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL15064657 | 0.73 | CNR2 (1.00) | CNR2ALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL15087793 | 0.73 | CNR2 (0.72) | CNR2ALDH1A1MEN1KMT2A | |
| SCHEMBL15064656 | 0.73 | CNR2 (1.00) | CNR2ALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL15064574 | 0.72 | CNR2 (1.00) | CNR2ALDH1A1KMT2ACNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170001949-A1 | NOVEL CANNABINOID RECEPTOR 2 (CB2) INVERSE AGONISTS AND THERAPEUTIC POTENTIAL FOR MULTIPLE MYELOMA AND OSTEOPOROSIS BONE DISEASES | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2017-01-05 | — | — | US | disclosed |
| US-9376380-B2 | Cannabinoid receptor 2 (CB2) inverse agonists and therapeutic potential for multiple myeloma and osteoporosis bone diseases | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2016-06-28 | — | — | US | disclosed |
| US-20140296294-A1 | NOVEL CANNABINOID RECEPTOR 2 (CB2) INVERSE AGONISTS AND THERAPEUTIC POTENTIAL FOR MULTIPLE MYELOMA AND OSTEOPOROSIS BONE DISEASES | UNIV PITTSBURGH (US) | 2014-10-02 | — | — | US | disclosed |
| US-8772541-B2 | Cannabinoid receptor 2 (CB2) inverse agonists and therapeutic potential for multiple myeloma and osteoporosis bone diseases | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2014-07-08 | — | — | US | disclosed |
| US-20130172388-A1 | NOVEL CANNABINOID RECEPTOR 2 (CB2) INVERSE AGONISTS AND THERAPEUTIC POTENTIAL FOR MULTIPLE MYELOMA AND OSTEOPOROSIS BONE DISEASES | UNIVERSITY OF PITTSBURGH -- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2013-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296294-A1 | NOVEL CANNABINOID RECEPTOR 2 (CB2) INVERSE AGONISTS AND THERAPEUTIC POTENTIAL FOR MULTIPLE MYELOMA AND OSTEOPOROSIS BONE DISEASES | CNR2, CNR1, GPR3 | CNR2 1/4885ALDH1A1 4617/4885TSHR 870/4885 |
| US-20170001949-A1 | NOVEL CANNABINOID RECEPTOR 2 (CB2) INVERSE AGONISTS AND THERAPEUTIC POTENTIAL FOR MULTIPLE MYELOMA AND OSTEOPOROSIS BONE DISEASES | CNR2, CNR1, GPR3 | CNR2 1/4885ALDH1A1 4572/4885TSHR 780/4885 |
| US-20130172388-A1 | NOVEL CANNABINOID RECEPTOR 2 (CB2) INVERSE AGONISTS AND THERAPEUTIC POTENTIAL FOR MULTIPLE MYELOMA AND OSTEOPOROSIS BONE DISEASES | CNR2, CNR1, GPR3 | CNR2 1/4885ALDH1A1 4617/4885TSHR 870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.